Antiviral Drug Discovery To Address the COVID-19 Pandemic

ABSTRACT The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery program...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Douglas D. Richman
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	coronavirus COVID-19 SARS-CoV-2 antiviral agents drug resistance hepatitis C virus Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/43566cc0f43b48138638aba667090e53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43566cc0f43b48138638aba667090e53
record_format	dspace
spelling	oai:doaj.org-article:43566cc0f43b48138638aba667090e532021-11-15T16:19:10ZAntiviral Drug Discovery To Address the COVID-19 Pandemic10.1128/mBio.02134-202150-7511https://doaj.org/article/43566cc0f43b48138638aba667090e532020-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02134-20https://doaj.org/toc/2150-7511ABSTRACT The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (Mpro) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.Douglas D. RichmanAmerican Society for MicrobiologyarticlecoronavirusCOVID-19SARS-CoV-2antiviral agentsdrug resistancehepatitis C virusMicrobiologyQR1-502ENmBio, Vol 11, Iss 5 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	coronavirus COVID-19 SARS-CoV-2 antiviral agents drug resistance hepatitis C virus Microbiology QR1-502
spellingShingle	coronavirus COVID-19 SARS-CoV-2 antiviral agents drug resistance hepatitis C virus Microbiology QR1-502 Douglas D. Richman Antiviral Drug Discovery To Address the COVID-19 Pandemic
description	ABSTRACT The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (Mpro) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
format	article
author	Douglas D. Richman
author_facet	Douglas D. Richman
author_sort	Douglas D. Richman
title	Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_short	Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_full	Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_fullStr	Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_full_unstemmed	Antiviral Drug Discovery To Address the COVID-19 Pandemic
title_sort	antiviral drug discovery to address the covid-19 pandemic
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/43566cc0f43b48138638aba667090e53
work_keys_str_mv	AT douglasdrichman antiviraldrugdiscoverytoaddressthecovid19pandemic
_version_	1718426899906035712

Antiviral Drug Discovery To Address the COVID-19 Pandemic

Ejemplares similares